Zydus Lifesciences gets USFDA tentative nod for two generic drugs
Zydus Lifesciences said it has received tentative approvals from the US health regulator to market two generic drugs.
Zydus Lifesciences on Wednesday said it has received tentative approvals from the US health regulator to market two generic drugs -- used for lowering blood pressure and for controlling diabetes, in the American market.
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Bosentan Tablets for oral suspension in 32 mg strength, the drug maker said in a regulatory filing. Bosentan Tablet for oral suspension is indicated for the treatment of pulmonary arterial hypertension (PAH) in pediatric patients aged three years and older.
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, it said. As per the latest IQVIA data, Bosentan Tablets for oral suspension had annual sales of USD 16 million in the US.
In a separate filing, the company said it has also received tentative approval from USFDA to market canagliflozin tablets of strengths 100 mg and 300 mg. The canagliflozin tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This drug will be manufactured at the group's formulation manufacturing facility at Moraiya, the company added.
U.S. Secretary of State warns China against aiding Russia in Ukraine war
Miscreants throw stones at Owaisi's Delhi residence; Police files complaint
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Retirement Planning: SIP+SWP combination; Rs 15,000 monthly SIP for 25 years and then Rs 1,52,000 monthly income for 30 years
EPF vs SIP vs PPF Calculator: Rs 12,000 monthly investment for 30 years; which can create highest retirement corpus
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
Home loan EMI vs Mutual Fund SIP Calculator: Rs 70 lakh home loan EMI for 20 years or SIP equal to EMI for 10 years; which can be easier route to buy home; know maths
12:30 PM IST